Swertiamarin
CAS: 17388-39-5
Ref. 3D-MS10475
1g | 865,00 € | ||
50mg | 180,00 € | ||
100mg | 260,00 € | ||
250mg | 406,00 € | ||
500mg | 544,00 € |
Produktinformation
- (4aR,5R,6S)-5-Ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-1H,3H-pyrano[3,4-c]pyran-1-one
- (4aR,5R,6S)-5-ethenyl-4a-hydroxy-1-oxo-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-6-yl beta-D-glucopyranoside
- (5R,6S)-5-ethenyl-4a-hydroxy-1-oxo-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-6-yl beta-D-glucopyranoside
- 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR-(4aalpha,5beta,6alpha))-
- 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-d-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, [4aR-(4aα,5β,6α)]-
- Brn 0055278
- Swertamarin
- Swertiamarine
- Mehr Synonyme anzeigen
- Swertiamaroside
- Swertimarin
- (4aR,5R,6S)-5-Ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-1H,3H-pyrano[3,4-c]pyran-1-one
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, [4aR-(4aα,5β,6α)]-
- 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-
Swertiamarin is a natural compound that has been shown to have anti-steatotic activity in animal models. Swertiamarin was found to reduce the activity index for liver steatosis and increase the activity index for hepatic steatosis, which may be due to its ability to inhibit 5-hydroxytryptamine (5-HT)2 receptors. Swertiamarin also inhibits the activation of c-jun N-terminal kinase, which is a protein involved in cellular events such as apoptosis and inflammation. The molecular docking analysis of swertiamarin with the human 5-HT2A receptor showed that swertiamarin binds to the receptor with high affinity, inhibiting its function. The use of swertiamarin in combination with other natural compounds could be used as an alternative treatment for hepatic steatosis in humans.
Chemische Eigenschaften
Technische Anfrage zu: 3D-MS10475 Swertiamarin
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.